Dear Experimental toxicologist,
I am a student at cambridge University and am new to the field of
experimental toxicology. For a project I am trying to get a sense of where
drug/bioteh companies tend to do preclinical animal toxicology in the drug
development pipeline. I have chatted with some people and realise that there
is no golden rule… it appears that it can be done as early as in the drug
discovery phase with a few trial screens just crudely assessing behavioural
change as an indicator of toxicity. Presumably it always ends with a double
mammal trial. Could somebody please point be to a resource or help me better
understand the stages in the pipeline when in vivo toxicology may want to be
done?
Best regards,
Matthijs van Leeuwen
-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://www.bio.net/bionet/mm/toxicol/attachments/20050725/a21df784/attachment.html
